Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE5A | O76074 | 20/20 | 0.54 |
| ▸ | PDE6C | P51160 | 2/20 | 0.46 |
| ▸ | PDE6D | O43924 | 1/20 | 0.46 |
| ▸ | PDE6A | P16499 | 1/20 | 0.46 |
| ▸ | PDE6G | P18545 | 1/20 | 0.46 |
| ▸ | PDE6B | P35913 | 1/20 | 0.46 |
| ▸ | PDE6H | Q13956 | 1/20 | 0.46 |
| ▸ | PDE11A | Q9HCR9 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6630217 | 0.86 | POLB (0.51) | PDE5APDE6CPDE11A | |
| SCHEMBL6629353 | 0.84 | PDE5A (0.56) | PDE5A | |
| SCHEMBL6629467 | 0.84 | PDE5A (0.57) | PDE5APDE6CPDE11A | |
| SCHEMBL6631340 | 0.82 | PDE5A (0.37) | PDE5APDE6CPDE11A | |
| SCHEMBL6629898 | 0.80 | PDE5A (0.62) | PDE5A | |
| SCHEMBL6630506 | 0.78 | PDE5A (0.58) | PDE5A | |
| SCHEMBL6630240 | 0.77 | PDE5A (0.53) | PDE5APDE6C | |
| SCHEMBL7079385 | 0.76 | PDE5A (0.47) | PDE5A | |
| SCHEMBL6629253 | 0.76 | PDE5A (0.65) | PDE5APDE6C | |
| SCHEMBL6630410 | 0.76 | PDE5A (0.57) | PDE5APDE6C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1368352-B1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LTD (GB) | 2004-12-01 | — | — | EP | claimed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | claimed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | claimed |
| EP-1368352-B1 | CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS | PFIZER LTD (GB) | 2004-12-01 | — | — | EP | disclosed |
| US-6770645-B2 | SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS | PFIZER INC. | 2004-08-03 | — | — | US | disclosed |
| US-20030064990-A1 | Pharmaceutically active compounds | PFIZER INC. | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030064990-A1 | Pharmaceutically active compounds | PDE5A, PDE3A, PDE2A | PDE5A 1/4885PDE6C 24/4885PDE6D 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.